retatrutide phase 2 results obesity nejm 2023 Once-Monthly Maridebart Cafraglutide for the Treatment of — A Trial GLP-1 Medications for Weight Loss:
Description
High doses of semaglutide (7.2 mg) caused the side effect in 22.9% of participants in experimental trials
This could be caused by residual GLP-1 in the OCS system
Months five through twelve typically show continued but decelerating weight loss
Cardiovascular Exercise Low to moderate-intensity cardio supports overall caloric expenditure and cardiovascular health
These are chemicals in the brain that help with mood, motivation, and energy
